Ascelia Pharma AB (OSTO:ACE)

kr 9 -0.23 (-2.49%) Market Cap: 303.82 Mil Enterprise Value: 296.08 Mil PE Ratio: 0 PB Ratio: 4.83 GF Score: 20/100

Q1 2024 Ascelia Pharma AB Earnings Call Transcript
May 16, 2024

kr9.5 (-6.68%)

Earnings
Q4 2023 Ascelia Pharma AB Earnings Presentation Transcript
Feb 09, 2024
Q3 2023 Ascelia Pharma AB Earnings Call Transcript
Nov 09, 2023

kr2.88 (-3.52%)

Earnings
Q2 2023 Ascelia Pharma AB Earnings Call Transcript
Aug 18, 2023

kr3.27 (-5.49%)

Earnings
Q4 2022 Ascelia Pharma AB Earnings Call Transcript
Feb 10, 2023

kr14.18 (+0.57%)

Earnings
Q3 2022 Ascelia Pharma AB Earnings Call Transcript
Nov 04, 2022

kr22.7 (+10.73%)

Earnings
Q2 2022 Ascelia Pharma AB Earnings Call Transcript
Aug 18, 2022

kr22 (-2.65%)

Earnings
Q1 2022 Ascelia Pharma AB Earnings Call Transcript
May 11, 2022

kr20.25 (-3.11%)

Earnings
Q4 2021 Ascelia Pharma AB Earnings Call Transcript
Feb 10, 2022

kr25.8 (+1.57%)

Earnings
Q2 2021 Ascelia Pharma AB Earnings Call Transcript
Aug 19, 2021

kr32.05 (-4.75%)

Earnings

Q4 2021 Ascelia Pharma AB Earnings Call Transcript

Feb 10, 2022 / 09:00AM GMT

Release Date Price: kr25.8 (+1.57%)

Transcript

Operator

Ladies and gentlemen, welcome to the Ascelia Pharma audiocast for teleconference Q4 2021. Today, I'm pleased to present the CEO, Magnus Corfitzen. (Operator Instruction) Magnus, please begin your meeting.

Magnus Corfitzen

Ascelia Pharma AB - CEO

Yeah. Thank you, operator. Welcome, everyone, to the webcast for Ascelia Pharma's fourth quarter 2021. So I'm Magnus Corfitzen, CEO of Ascelia Pharma. And with me today, I have Kristian Borbos, our Chief Financial Officer; Julie Brogren, our Chief Commercial Officer; and Andreas Norlin, VP of R&D.

Our regular followers will notice that Andreas has joined instead of our Chief Medical Officer, Carl Bjartmar, on this call. This is a temporary support we have here, as Carl is traveling and, right now, meeting with an investigator in the SPARKLE study. So we're really happy to have Andreas joining us today.

Now please turn to page number 2. We will be making certain forward-looking statements on this call, so please pay close attention to this before moving to slide number 3.

Ascelia Pharma

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.